<DOC>
	<DOC>NCT01325428</DOC>
	<brief_summary>The general aim of this study is to investigate the efficacy and safety of afatinib alone and in combination with weekly vinorelbine (in patients who progress on afatinib monotherapy within this trial) as treatment in patients with HER2-overexpressing, locally advanced or metastatic inflammatory breast cancer. The study will include patients who have and have not failed prior trastuzumab treatment.</brief_summary>
	<brief_title>Afatinib (BIBW2992) in HER2 (Human Epidermal Growth Factor Receptor 2)-Overexpressing Inflammatory Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Inflammatory Breast Neoplasms</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Inclusion criteria: 1. Female patients &gt;=18 years with proven diagnosis of HER2overexpressing, histologically confirmed breast cancer 2. Locally advanced or metastatic disease 3. Must have disease that can be evaluated according to RECIST 1.1 (Response Evaluation Criteria for Solid Tumours version 1.1) 4. For trastuzumab pretreated patients, must have failed prior trastuzumab treatment 5. Investigatorconfirmed diagnosis of Inflammatory Breast Cancer 6. Must have biopsiable disease Exclusion criteria: 1. Prior treatment with HER2targeted small molecules or antibodies other than trastuzumab (which must have been given in the trastuzumabfailure study population) 2. Must not have received prior vinorelbine treatment</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>